United States Gene Therapy Market to hit US$ 13.26 Billion by 2033, Driven by Rising Prevalence of Genetic Disorders and Advancements in Gene Editing and Viral Vector Technologies

The Gene Therapy Market reached US$ 5.91 billion in 2025 and is expected to reach US$ 44.20 billion by 2033, growing at a CAGR of 23.1% during the forecast period 2026-2033. Growth is driven by increasing prevalence of genetic disorders, cancer, and rare diseases worldwide. Rising advancements in gene editing technologies and viral vector development are accelerating market expansion. The growing number of clinical trials and regulatory approvals for gene-based treatments is further supporting demand. Additionally, increasing investments from biotechnology and pharmaceutical companies are boosting innovation. Expanding adoption of personalized medicine and regenerative therapies is also contributing to strong market growth.

Download PDF Sample Report:
https://www.datamintelligence.com/download-sample/gene-therapy-market?prasad

Gene Therapy Market Major Players:

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a global leader in RNA interference (RNAi)-based therapeutics, with strong relevance in the broader gene therapy market. In 2025, the company reported revenue of USD 3.0 billion, driven by commercialization of rare disease treatments. In the gene therapy market, Alnylam plays a major role by advancing gene-silencing technologies that target disease-causing genes at the RNA level. Its platform enables precision treatment of rare genetic disorders, liver diseases, and metabolic conditions, making it a key innovator in next-generation genetic medicine approaches.

Spark Therapeutics, Inc.

Spark Therapeutics, a subsidiary of Roche Holding AG, is a pioneering gene therapy company focused on transformative treatments for genetic diseases. In 2025, Roche reported revenue of USD 70.0 billion, with Spark contributing to its advanced therapeutics portfolio. In the gene therapy market, Spark plays a key role through its adeno-associated virus (AAV)-based gene therapies, particularly in ophthalmology and rare genetic disorders. Its technologies aim to deliver long-term or potentially one-time treatments by correcting defective genes at the source.

Novartis AG

Novartis is one of the world's leading pharmaceutical companies with strong capabilities in advanced therapies and gene therapy development. In 2025, Novartis reported revenue of USD 52.0 billion, driven by oncology, cardiovascular, and rare disease treatments. In the gene therapy market, Novartis plays a major role through its investments in cell and gene therapies such as CAR-T and AAV-based treatments. Its gene therapy portfolio focuses on treating spinal muscular atrophy and other rare genetic conditions, positioning it as a key player in commercializing advanced genetic medicines.

Find the Right Partner to Accelerate Your Growth Today with Our Latest Report:
https://www.datamintelligence.com/partner-identification-enquiry/gene-therapy-market?prasad

United States: Recent Industry Developments

✅ In March 2026, Novartis AG (U.S. operations) expanded gene therapy pipeline for rare diseases. The innovation improves treatment outcomes. Novartis continues advancing cell and gene therapies.

✅ In February 2026, Pfizer Inc. enhanced gene therapy programs targeting genetic disorders. The development improves clinical success rates. Pfizer continues strengthening biotech portfolio.

✅ In January 2026, Bluebird Bio expanded gene therapy treatments for hematological conditions. The initiative improves patient access. Bluebird continues advancing innovation.

✅ In December 2025, Spark Therapeutics enhanced AAV-based gene therapies for rare diseases. The development improves delivery systems. Spark continues strengthening pipeline.

Japan: Recent Industry Developments

✅ In March 2026, Takeda Pharmaceutical Company expanded gene therapy research and manufacturing capabilities. The innovation improves scalability. Takeda continues advancing advanced therapies.

✅ In February 2026, Astellas Pharma enhanced gene therapy pipeline for oncology and rare diseases. The development improves treatment outcomes. Astellas continues strengthening biotech innovation.

✅ In January 2026, Daiichi Sankyo expanded gene-based therapies for targeted treatment. The initiative improves precision medicine. Daiichi Sankyo continues advancing R&D.

✅ In December 2025, Otsuka Pharmaceutical enhanced research collaborations in gene therapy. The development supports innovation. Otsuka continues strengthening healthcare portfolio.

Segment Covered in the Gene Therapy Market:

By Approach: In-Vivo
In-vivo gene therapy dominates the gene therapy market as it enables direct delivery of genetic material into the patient's body, reducing complexity and cost compared to ex-vivo methods. It is widely used for treating genetic disorders, oncology indications, and rare diseases where direct targeting is critical.
In-vivo approaches account for approximately 58% of the total market. Based on a global market size assumption of USD 12.6 billion in 2025, this translates to an estimated segment value of USD 7.3 billion. Growth is driven by increasing clinical approvals, advancements in delivery technologies, and expanding therapeutic applications.

By Vector Type: Viral Vectors
Viral vectors dominate the market due to their high efficiency in delivering genetic material into target cells. They are widely used in approved gene therapies and clinical-stage pipelines, particularly adeno-associated viruses (AAV) and lentiviral vectors.
This segment accounts for approximately 71% of the total market. Based on the USD 12.6 billion global market size in 2025, this corresponds to an estimated value of USD 8.9 billion. Growth is driven by increasing gene therapy approvals, strong clinical success rates, and expanding research investments.

By Technique: Gene Addition
Gene addition is the leading technique as it remains the most established and widely used method in commercial gene therapies. It involves introducing functional gene copies to compensate for defective or missing genes.
This segment accounts for approximately 46% of the total market. Based on the USD 12.6 billion global market size in 2025, this translates to an estimated value of USD 5.8 billion. Growth is driven by increasing adoption in rare genetic disorders and strong regulatory approvals.

By Application: Oncology
Oncology dominates the gene therapy market due to the rising prevalence of cancer and strong development of gene-based immunotherapies such as CAR-T cell therapies and oncolytic virus therapies.
This segment accounts for approximately 33% of the total market. Based on the USD 12.6 billion global market size in 2025, this corresponds to an estimated value of USD 4.2 billion. Growth is driven by increasing cancer burden, strong clinical pipelines, and rising investment in precision oncology.

Market Segmentation

The Gene Therapy Market is segmented by approach into in-vivo and ex-vivo; by vector type into viral vectors and non-viral vectors; by technique into gene addition, gene silencing, and gene editing; by application into rare diseases, musculoskeletal conditions, blood disorders, oncology, ophthalmology, and others; and by region into North America, Latin America, and Europe.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/gene-therapy-market?prasad

Regional Analysis

North America
North America is the leading market due to strong biotechnology infrastructure, high R&D investments, and rapid regulatory approvals for gene therapies. The region is led by the United States.
The North American market is estimated at approximately USD 5.4 billion in 2025, accounting for about 43% of the global market. Growth is driven by increasing gene therapy approvals, strong funding ecosystem, and advanced clinical research capabilities.

Europe
Europe is a significant market supported by strong research institutions, regulatory support, and increasing adoption of advanced therapeutics. Key contributors include Germany, France, and the United Kingdom.
The European market is valued at approximately USD 4.0 billion in 2025, representing about 32% of the global market. Growth is driven by expanding clinical trials, government funding, and rising focus on rare disease treatments.

Latin America
Latin America is an emerging market driven by improving healthcare infrastructure, increasing awareness of advanced therapies, and gradual adoption of gene-based treatments, with Brazil and Mexico as key contributors.
The market is estimated at approximately USD 3.2 billion in 2025, accounting for about 25% of the global market. Growth is supported by rising investment in biotechnology and expanding access to advanced healthcare solutions.

Data-Driven Research Methodology for the Gene Therapy Market:

Our research process for the Gene Therapy Market at DataM Intelligence combines rigorous primary and secondary research to ensure accurate and reliable insights. We engage with industry experts, key stakeholders, and validated data sources to capture real-time market dynamics. Advanced analytical tools and proprietary models are applied to forecast trends, competitive landscapes, and growth opportunities. Each report undergoes multi-level validation to deliver actionable intelligence that supports strategic decision-making.

Purchase the Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=gene-therapy-market?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us-
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us
DataM Intelligence is a market research and consulting firm that delivers comprehensive end-to-end business solutions, covering everything from in-depth research to strategic consulting. The company leverages key industry trends, insights, and developments to provide fast, reliable, and actionable solutions tailored to diverse client requirements.
It offers both syndicated and customized research reports supported by a strong and robust methodology. With an extensive database comprising 9000+ reports across 40+ industry domains, DataM Intelligence serves over 200 companies in more than 50 countries, helping organizations access critical business intelligence that drives informed decision-making and sustainable growth.

This release was published on openPR.